Generic drugs were substituted for brand-name drugs 93% of the time in 2010, but whether increased use of generics is actually saving money is up for debate, according to the Government Accountability Office (GAO).
Studies looking at cost savings from use of generic drugs "had mixed results regarding the effect of using these generics, in that some found they raised healthcare costs, while others found they led to cost savings," wrote the authors of a GAO report released Thursday.
The GAO report was requested by Sen. Orrin Hatch, co-author of the 1984 Hatch-Waxman Act, which paved the way for a major increase in the number of generic drugs. In the early 1980s, there were generic versions of just 35% of the top-selling drugs with expired patents; by the late 1990s, almost all of them had generic versions.
Prescription drug spending more than tripled from 2001 and topped $307 billion in 2010, making up 12% of all healthcare spending in the country, the GAO researchers wrote.
Read more at: http://tinyurl.com/7s37fjj
Source: MedPage Today
Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 1
November 10th 2023In part 1 of this 2-part podcast, a panel of experts discusses the provider and payer considerations for transitioning patients to biosimilars, approaches to prescribing biosimilars over reference products, and more.
Listen
Disease-Modifying Antirheumatic Drugs Linked to Decreased Risk for Autoimmune Thyroid Disease
November 28th 2023A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.
Read More